Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Shares OutstandingShares Outstanding
Ratios

Medifast (MED) Receivables - Net (2016 - 2021)

Medifast's Receivables - Net history spans 12 years, with the latest figure at $88000.0 for Q1 2021.

  • For Q1 2021, Receivables - Net fell 77.44% year-over-year to $88000.0; the TTM value through Mar 2021 reached $88000.0, down 77.44%, while the annual FY2020 figure was $584000.0, 59.36% down from the prior year.
  • Receivables - Net reached $88000.0 in Q1 2021 per MED's latest filing, down from $584000.0 in the prior quarter.
  • In the past five years, Receivables - Net ranged from a high of $1.5 million in Q1 2017 to a low of $88000.0 in Q1 2021.
  • Average Receivables - Net over 5 years is $865882.4, with a median of $914000.0 recorded in 2017.
  • Peak YoY movement for Receivables - Net: soared 75.52% in 2018, then plummeted 77.44% in 2021.
  • A 5-year view of Receivables - Net shows it stood at $576000.0 in 2017, then surged by 75.52% to $1.0 million in 2018, then surged by 42.14% to $1.4 million in 2019, then crashed by 59.36% to $584000.0 in 2020, then tumbled by 84.93% to $88000.0 in 2021.
  • Per Business Quant, the three most recent readings for MED's Receivables - Net are $88000.0 (Q1 2021), $584000.0 (Q4 2020), and $647000.0 (Q3 2020).